UNSPSC 51343201: Raltegravir

This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VKV8053U. European Medicines Agency schedules Raltegravir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25667. Raltegravir generally arises in the molecular formula C20H21FN6O5. The term RALTEGRAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.) As of Q4 2014, RALTEGRAVIR remains the US FDA Preferred Term for this commodity.

Raltegravir bears US NLM identifiers UMLS ID C1871526 and NCI Concept Code C72837. SMILES: CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F.

UNSPSC 51343201 Raltegravir is a Commodity code that does not align with the state and local procurement activity currently posted under it. The recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, emergency medical and first-aid supplies for fire departments, and generic multi-source pharmaceuticals and over-the-counter products — none of which relate to raltegravir, an antiretroviral medication for HIV treatment. The mismatch between the code's nominal scope and the actual solicitations suggests either a cataloging error in the tagging system or that raltegravir procurement activity is too sparse to surface in recent state and local notices.

The representative opportunities shown involve health departments, fire departments, state pharmacy benefit programs, and cooperative purchasing alliances across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for naloxone and drug deactivation systems; the City of Tampa posted an IFB on March 25, 2026 for emergency medical supplies to the Fire Department Rescue Division with an estimated contract value of $700,000 and a 5 percent small local business enterprise discount; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer pharmacy initiatives; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 due March 26, 2026 for generic pharmaceuticals and OTC products through authorized wholesalers. Actual raltegravir procurement under this code warrants direct inquiry with specific state Medicaid agencies or health departments rather than reliance on this code's recent activity.